AI Prospecting for Regeneron Pharmaceuticals
Company data:
Company size:
13926 employeesWebsite URL:
https://www.regeneron.comIndustry
BiotechnologyHeadquarters:
777 Old Saw Mill River Road, Tarrytown, NY 10591, USAInvestment round:
Publicly Traded (NASDAQ: REGN)ARR:
$12 billionKey stakeholders
These are the current top-level decision-makers at the company and their LinkedIn profiles. Check them for recent activity and updates
Latest news about Regeneron Pharmaceuticals
Here are some of the most recent media mentions. Use them in your sales prospecting to qualify a prospect's buyer intent and personalize outreach with the latest company updates
Regeneron Pharmaceuticals will report its first quarter 2025 financial and operating results on April 29, 2025, before the U.S. market opens, followed by a conference call and webcast at 8:30 AM Eastern Time[5].
Regeneron Pharmaceuticals has reached a settlement and license agreement with Biocon Biologics to commercialize the aflibercept biosimilar, Yesafili, in the US. This agreement allows for a launch in the second half of 2026 or earlier, resolving pending patent and litigation issues[3].
The FDA has accepted Regeneron's supplemental biologics license application (sBLA) for priority review of EYLEA HD (aflibercept) for the treatment of macular edema following retinal vein occlusion and to broaden the dosing schedule to include every-4-week dosing across approved indications, with a target action date of August 19, 2025[3][4].
Open job positions at Regeneron Pharmaceuticals
This company is actively hiring to fill these roles. Use this for sales prospecting if your solution assists, augments, or provides an alternative for the growing team and position.
Associate Director Marketing Operations
Federal Account Director
Sr Statistical Programmer
